Teva Pharmaceutical Industries Ltd (TEVA.TA) said Friday it aims to win U.S. approval by late 2017 or early 2018 for its version of Mylan NV's EpiPen device for treating severe allergic reactions, a move that would challenge the branded product's overwhelming market dominance.
Teva's application for a copycat version has been in question since February, when the Food and Drug Administration flagged "major deficiencies" in the Israeli drugmaker's device.
Read Full Article »